LOGIN
Loading...
Search Filters
Date Range
toReport Types
Condition
See all (49)
Region of the Body
See all (19)
Specialties
See all (18)
Emerging Treatments
OE Recommends Topics
Multimedia
Journal
Conference Series
Evidence Series
Showing 1 - 20 of 490
Adherence to weekly oral BP therapy versus quarterly IV BP therapy at varying health literacy level
J Bone Miner Metab. 2018 Sep;36(5):589-595. doi: 10.1007/s00774-017-0867-y
Effectiveness of Alendronate versus Alfacalcidol in maintaining bone mineral density
Journal of Bone and Joint Surgery American; 2011; 93(A); 1203-1209
Improved bone mineral density up to 12 months with a 6-month oral alendronate intervention
J Bone Joint Surg Am. 2006 Feb;88(2):267-72
Etidronate, alendronate, and reisendronate significantly reduce the risk of hip fracture
Curr Med Res Opin. 2011 Jun;27(6):1141-8. doi: 10.1185/03007995.2011.570747. Epub 2011 Apr 1
Denosumab is superior to alendronate for improving cortical bone porosity post-menopause
Bone. 2014 Feb;59:173-9. doi: 10.1016/j.bone.2013.11.016. Epub 2013 Nov 22.
Oral alendronate cannot yet be recommended for children with OI
J Clin Endocrinol Metab. 2011 Feb;96(2):355-64
Teriparatide increases BMD in patients with glucocorticoid-Induced osteoporosis
N Engl J Med. 2007 Nov 15;357(20):2028-39
Alendronate improves bone mineral density after total knee arthroplasty
J Bone Joint Surg Am. 2003 Nov;85-A(11):2121-6
Compliance to oral bisphosphonate therapy similar regardless of follow-up type
Osteoporos Int. 2014 Apr;25(4):1345-55. doi: 10.1007/s00198-013-2610-4. Epub 2014 Jan 21.
Effect of teriparatide versus alendronate or no medication on periprosethtic BMD in THA
J Arthroplasty. 2016 Jan;31(1):333-8
Alendronate is superior to alfacalcidol in preventing glucocorticoid-induced bone loss
N Engl J Med. 2006 Aug 17;355(7):675-84
Discontinuing alendronate after 5 years of treatment, does it affect fracture risk?
JAMA. 2006 Dec 27;296(24):2927-38.
Alendronate treatment for fibrous dysplasia, a rare skeletal disorder
J Clin Endocrinol Metab. 2014 Nov;99(11):4133-40.
Denosumab increases bone mass but does not reduce fracture risk compared to alendronate
Int J Clin Pract. 2012 Apr;66(4):399-408. doi: 10.1111/j.1742-1241.2011.02806.x. Epub 2012 Feb 7
Alendronate & zoledronate both reduce hip and vertebral fracture risk compared to placebo
Gynecol Endocrinol. 2013 Dec;29(12):1005-14. doi: 10.3109/09513590.2013.813468. Epub 2013 Sep 25
Network meta-analysis of anti-osteoporosis therapies for oral glucocorticoid users
Osteoporos Int. 2016 Jun;27(6):1989-98
Bisphosphonate treatment maintains positive effect on bone loss at 6 year follow-up
J Orthop Res. 2009 Feb;27(2):183-8
Combined parathyroid hormone+alendronate therapy versus PTH monotherpy for osteoporosis
J Invest Surg. 2015 Dec;28(6):309-16
Bisphosphonates in revision THA ineffective in altering pseudomembrane cytokine expression
J Arthroplasty. 2010 Sep;25(6):958-63
The role of alendronate in osteoporosis patients undergoing PLIF
J Neurosurg Spine. 2011 Apr;14(4):500-7. doi: 10.3171/2010.11.SPINE10245. Epub 2011 Jan 28
Showing 1 - 20 of 490